1. Home
  2. HFFG vs LCTX Comparison

HFFG vs LCTX Comparison

Compare HFFG & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HF Foods Group Inc.

HFFG

HF Foods Group Inc.

HOLD

Current Price

$2.37

Market Cap

136.3M

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.69

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HFFG
LCTX
Founded
1997
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Food Distributors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.3M
407.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HFFG
LCTX
Price
$2.37
$1.69
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.25
AVG Volume (30 Days)
86.5K
1.3M
Earning Date
11-10-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,225,541,000.00
$10,816,000.00
Revenue This Year
$4.36
$5.24
Revenue Next Year
$3.35
$126.78
P/E Ratio
N/A
N/A
Revenue Growth
4.10
24.05
52 Week Low
$1.70
$0.37
52 Week High
$4.93
$2.09

Technical Indicators

Market Signals
Indicator
HFFG
LCTX
Relative Strength Index (RSI) 41.41 46.72
Support Level $2.52 $1.65
Resistance Level $2.66 $1.82
Average True Range (ATR) 0.12 0.08
MACD -0.02 0.00
Stochastic Oscillator 10.75 48.00

Price Performance

Historical Comparison
HFFG
LCTX

About HFFG HF Foods Group Inc.

HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The company's business consists of one operating segment; HF Group, which operates solely in the United States. The company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: